A “smart contact lens” can monitor eye pressure and manage and release glaucoma drugs to counteract any rises in this, preclinical research suggests.
The all-polymer, microfluidic lens, described in Science Translational Medicine, represents further progress towards personalized eye technologies in a “theranostic” approach that combines diagnostics and therapy.
The battery-free device was able to monitor intraocular pressure—the most prominent, modifiable risk factor for glaucoma—and could release glaucoma drugs timolol and brimonidine at pressure thresholds in animal studies.
【MORE】